Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Cancer
- Intractable Pain
- Neuropathic Pain
- Pain
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.
The purpose of this study is to evaluate the effects and the tolerability of intrathecal ziconotide in cancer patients suffering from severe neuropathic pain not controlled by previous therapies.
Tracking Information
- NCT #
- NCT00996983
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Arturo Cuomo, M.D. NCI Naples, Division of Pain Therapy Principal Investigator: Gennaro Russo, M.D. NCI Naples, Division of Pain Therapy Principal Investigator: Alessandro Morabito, M.D. NCI Naples, Clinical Trials Unit
Get Well Soon